Affinity Express Management Team and LiveIt Acquire Outsourced Graphic and Design Services Leader

Affinity Express Management Team and LiveIt Acquire Outsourced Graphic and Design Services Leader

January 11, 2007

Chicago, January 11, 2007–James R. Daleen, president and chief executive officer of Affinity Express, Inc., announced that the company’s management team, in partnership with LiveIt Solutions, Inc., the holding company for Ayala Corporation’s investments in the Business Process Outsourcing (BPO) sector, has acquired 100% of the Delawareincorporated
company.

Affinity Express is the leading provider of outsourced graphic and design services for more than 3,000 clients worldwide in several industries, including:

IntelliVid

Retailers Invited to Participate in IntelliVid's Proof-of-Value Program to Test Its Video Analytics Solution

Retailers Invited to Participate in IntelliVid's Proof-of-Value Program to Test Its Video Analytics Solution

February 26, 2007

IntelliVid Proposes to Increase Retailers' Operating Incomes by Nine Percent by Decreasing Shrink 25 Percent
Cambridge, MA, February 26, 2007 -- IntelliVid Corporation today announced its Proof-of-Value Program, created to benchmark the effectiveness of video analytics systems in the retail industry.

Hypnion, Inc.

Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275

Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275

January 5, 2007

Primary and Secondary Efficacy Endpoints
Achieved Statistical Significance

Study Validated Drug's Unique H1 / 5HT2a
Mechanisms of Action

Drug Was Very Well Tolerated

Hypnion, Inc.

Lilly Announces Acquisition of Hypnion

Lilly Announces Acquisition of Hypnion

March 5, 2007

Deal Will Bolster Lilly's Sleep Disorder Research With Promising Insomnia Compound

Hypnion, Inc.

Lilly Announces Completion of Hypnion Acquisition

Lilly Announces Completion of Hypnion Acquisition

April 3, 2007

INDIANAPOLIS, April 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

AVEO Pharmaceuticals, Inc.

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

January 4, 2007

AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio

BG Medicine, Inc.

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

January 30, 2007

BG Medicine today announced the initiation of a multi-year research project, funded by Merck, AstraZeneca and Philips Medical, aimed at better understanding high risk plaque in heart attack and stroke.  The project will harness BGM’s systems biology measurement approaches along with state-of-the art medical imaging techniques to identify new approaches for the detection and treatment of vulnerable patients.

Epitome Biosystems

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

January 31, 2007

Waltham, MA, and Madison, WI, January 31, 2007 – Epitome Biosystems and EMD Biosciences Inc. announced today the successful completion of a collaboration to develop multiplex assays to measure phosphorylation of cell signaling proteins using Epitome’s EpiTag™ technology. Epitome developed custom antibody and peptide reagents to enable quantitative protein measurements of selected targets for EMD Biosciences. This completes the first commercial partnership for Epitome.

Adnexus Therapeutics

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

February 2, 2007

Angiogenesis Inhibitor, CT-322, Shows Biological Activity at First Dose Level Tested

Helicos BioSciences Corporation

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

February 9, 2007

The company’s researchers have developed proprietary nucleotide-polymerase formulations that enable sequencing through homopolymers.